0000000000242447

AUTHOR

Laura Biganzoli

showing 3 related works from this author

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

2013

The first-generation taxanes, conventional paclitaxel and docetaxel, are established treatment options for adjuvant and metastatic breast cancer (MBC). However, these agents have limitations, including primary/secondary resistance and harsh toxicities. The introduction of paclitaxel albumin represents a significant advance in taxane therapy as the first of a new generation of taxanes. This agent utilizes albumin pathways to achieve enhanced and targeted drug delivery to the tumour. The lack of solvent also means that it is well tolerated, despite the lack of premedications. Paclitaxel albumin is licensed in the United States and Europe as ≥2nd-line therapy in MBC (260mg/m(2) once every thre…

OncologyBridged-Ring Compoundsmedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsPharmacologychemistry.chemical_compoundBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMolecular Targeted TherapyNeoplasm MetastasisChemotherapyClinical Trials as TopicTaxanebusiness.industryHematologymedicine.diseaseMetastatic breast cancerTreatment OutcomeOncologyPaclitaxelchemistryTargeted drug deliveryDocetaxelFemaleTaxoidsbusinessAdjuvantmedicine.drugCritical reviews in oncology/hematology
researchProduct

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patient…

2020

<b><i>Background:</i></b> Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. <b><i>Methods:</i></b> For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). <b><i>Res…

Oncologymedicine.medical_specialtymedicine.drug_classPopulationAnastrozoleNOInternal medicineFulvestrant · First-line setting · Hormone receptor positive Advanced breast cancermedicineAdjuvant therapyProgression-free survivaleducationFulvestrantFirst-Line settingeducation.field_of_studyHormone receptor positiveAromatase inhibitorFulvestrantEVAbusiness.industrytrialsCancerEndocrine TherapyGIM-13medicine.diseaseEndocrine Therapy HR+/HER2– Advanced Breast Cancer High-Dose Fulvestrant First-Line setting EVA GIM-13 AMBRA trialsAdvanced breast cancer; First-line setting; Fulvestrant; Hormone receptor positiveOncologyHR+/HER2–Advanced Breast CancerSurgeryAMBRAbusinessHigh-DoseTamoxifenResearch Articlemedicine.drug
researchProduct

Assessment and treatment of elderly people with cancer: Italian (AIOM–SIGG) onco-geriatric survey results

2012

medicine.medical_specialtyOncologybusiness.industryFamily medicineElderly peopleMedicineCancerSurvey resultGeriatrics and Gerontologybusinessmedicine.diseaseJournal of Geriatric Oncology
researchProduct